Clinical trial NCT04436497: HEALEY ALS Platform Trial - Regimen A Zilucoplan
Official title: HEALEY ALS Platform Trial - Regimen A Zilucoplan
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Amyotrophic Lateral Sclerosis
Keywords: ALS
Placebo-Controlled
Double-Blind
Regimen-Specific Appendix
Lou Gehrig's Disease
Zilucoplan
Ra Pharmaceuticals
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Ra Pharmaceuticals
First posted: 2020-06-18
Enrollment: 162
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.

Detailed description: The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.

Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.

If a participant is randomized to Regimen A - Zilucoplan, the participant will complete a screening visit to assess additional Regimen A eligibility criteria. Once Regimen A eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active zilucoplan or matching placebo.

Regimen A will enroll by invitation, as participants may not choose to enroll in Regimen A. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen A.

For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.

Eligibility criteria: Inclusion Criteria:

* The following inclusion criterion is in addition to the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

  1. Vaccination with a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of study drug at the Baseline (Day 0) visit. Meningococcal vaccines (including boosters) should be administered in accordance with the study's vaccination worksheet.

Exclusion Criteria:

* The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).

  1. History of meningococcal disease.
  2. Prior treatment with a complement inhibitor.

Primary outcomes:
measure: Disease Progression as Assessed by the ALSFRS-R Total Score
timeFrame: Baseline through 24 Weeks
measure: Mortality Event Rate
timeFrame: Baseline through 24 Weeks
Secondary outcomes:
measure: Respiratory Function
timeFrame: Baseline and 24 Weeks
measure: Muscle Strength
timeFrame: Baseline and 24 Weeks
measure: Number of Participants That Experienced Death or Death Equivalent
timeFrame: Baseline through 24 Weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Healey Center for ALS at Mass General
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Merit Cudkowicz
role: PRINCIPAL_INVESTIGATOR
References: